Overview

Hydrogen's Safety and Efficacy as a Therapy in ECPR

Status:
Not yet recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this project is to test the feasibility and safety of inhaled hydrogen gas (H2) administration as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation (ECPR, i.e. mechanical circulatory support). Under exemption from informed consent, patients undergoing refractory cardiac arrest in the cardiac ICU at a participating center will be randomized to standard therapy with or without the administration of 2.4% hydrogen in gases administered via the ventilator and ECMO membrane for 72 hours.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Children's Hospital
Collaborator:
Baylor College of Medicine